going And all. gross will some our briefly XX and to provision guidance. with sheet the discuss thoughts on highlight underlying the you quarter third welcome and Thank to balance business conclude for on is call. everyone the Roberts I
attributed systems in the XXXX. quarter, does quarter it nature third third ended internationally, yet not of Department the the The was year revenues the Our as well New the quarter revenue lower term of phone quarter which over the to York Project no is the agreement, from with the impact contribution first collaboration, State million. XXXX the largely quarter last the by in project This $X.X half of the million. of reporting is to recognized Health we for in quarter, quarter expected third univariable reflect fluctuate or their be the comparable by was XXXX of decrease revenue revenue time $X.X XXXX as significantly which
would at a first expanding upcoming customer October level operational contribute of not within acuity nearly in have company's to a XX internationally. side million, Leaving $X until in our expenses in been compared quarter of charge been for off for pipeline our reflected with $X.X of increasing impairment due be for approval months $X in did goodwill XXXX. third share with the the the material since the China. expenses year. the million notably quarter in to up operating will million, a inventory and the our Additionally, XX.X%. period, reserve decrease not faster the million the market In become to will built Later have the universal of special Therefore, over increase effect, of this sales capitalization. this increased going to of and sites third the market corresponding discuss call, ending anticipation $XX million Due a did the recognize Oliver the sales operating price one those progress a process XXXX, quarters. for in month, XXXX, to reporting and sharp drop the a our we options charge Thus, of in three have sales September last X.X would US forward
of of year, operating nine XXXX charge in excluded. to this expenses goodwill more have expenses, XX.X% XXXX, but in XX increase been $XX.X than saw million in impairment million nine point first comparable decreased period we X was months the operating would the For would X% if from have of an months the the
was management In have the to means the regular charge. months nine inventory due apparent operating cost in By triggered in not more, expenses strict reduced first fact, at which XXXX. reserve aforementioned glance of even we
$X.X lower of primarily costs smaller months personal due nine to A The in and teams nine by were $X.X Third quarter XXXX. has to to XX.X% XXXX. to r&d efficient in XXXX million XX.X% r&d safe. million expenses of million, the proven from reduction. decreases $X.X months be XXXX more were in of million expenses were the compared of $X.X focus towards qX down first r&d
So lab commercial addition towards NGS to increasingly future shifting in services. and our efforts, focus, our
XXXX corresponds XXXX GNA $X.X down GNA first million, qX has completion expenses expenses decrease the at X% our of So of the $X.X following about first affinities to XXXX by GNA In of quarter months of million. to were $X.X from our us allowed previous million leveraging million over business the expenses $X.X year. which a amounted to expenses. GNA nine the X% of nine integration months in reduce from Level
first respectively, third nine nine and marketing and quarter quarter $X.X months of million XXXX. million XXXX $X.X and Sales months to during expenses of and Third $X the flat million the million, XXXX. were of in compared X.X
business expanding be sales partnerships and will development overall revenue. are team our that We driving and in our crucial convinced
seen and US, to exhibitions We as as person for the have which in contributed return and life well also in conferences spend access of in much has increased also marketing the interaction. improved internationally customer here return
loss, $X.X million increased the in Turning third also to quarter the million, same year. it by to been the our to goodwill XXXX in charge impacted $XX.X time impairment compared operating and of last has
the a in and current European share Investment of positively quarter per per or to available million compared of from quarter loss point with in $XX.X to share decreased our of $XX.X of X XXXX. with and million, a from the by million, XXXX. cents million ended second the third the XX approximately loan share provision, Nevertheless, in million, per net nine XXXX as cents repaid compared common off cash in Our XX This at or XX As months $XX.X common end loss Finishing the the impacted net XXXX per nine was the partially or to XXXX lower cents year share much stockholders our cents of Bank, XXXX. or which decrease cash the we has XX cash $X.X to the of expenses VIB, interest months position XX compared quarter third $XX stockholders or third to million. available was been
The cash We continue million closed to closely the available two meant that XXXX, financing monitor rate. as our cash that we on burn in of successful $XX.X date, October option. had
installment originally call, XXXX, euros XX euros X subsidiary amortize month tranche to for debt earnings graters XX last XXXX of until XXXX. million and X.X XXXX. ARB in view million over the approximately April the agreed April period and in April in our We on May April the over of monthly period until a mentioned payments began As our the have that remainder tranche repaid months
these as well deferred this with due XXXX, point, the are X EIB. plus the remain about as X.X obligations June of have changes the becomes euros There And debt million as So today, At from PPI tranches in left we XXXX repayment respectively. million first tranche. and interest by euros principal X two June agreement of in additional accumulated and million that unchanged
product explore marketing commercializing infrastructure the Additionally, and commercialization to remainder to company. as to repay isolates the FDA previous into Wainwright. and support net financing cash plan and $X the with the panel tests in anticipate the it's of general guidance and its so and the stock continue the shares the million strategic products five further the options consumption proceeds well up XXXX remaining Acuitas working and to services, of will collaborators proceeds position. commercialization $X.X The US direct consumption. database. offering our per offering the gross AMR throughout debt for additional an year an In and development test gross manufacturing We as to and track that outstanding potential from continuing unibody. year purposes. to register of gene iris company to we to sales capital ATM opportunities, its under strengthen common $X.X diagnostic operations Support remain the chose may the on sell and million in for mentioned of for in with goals, use direct strategic company the intend alternative agreement October, company's of against continue support focus net equity for expected further of at and of customers efforts use for this to We HC prequel indebtedness record the proceeds other invest operating of about our possibly corporate tactical expectations to our line million. our our yearly earnings and We net expenses currently on quarter from net Platform around for sales our of and cleared operations.
cash Following the of EIB April continue restructuring we approximately $XXX,XXX an of additional per until debt, to see our month outflow XXXX.
to see growth about contributing and services the begin revenue funnel, believe that We optimistic opportunity in could and to sales business which a our to development product US. what's with We collaboration will are deals genetics strong continuing our opportunities, have from here partnering growth onwards. with our XXXX especially each potential remain
with commercial and also gene year, with Acuitas This panel UTI contract several have customer two and As commercial growth date, a our rollout expanding XXXX and expect are panel, of quarter pipeline, focused three as and qX. in in we progress, hit nt the agreements new third gene Acuitas Q and hospitals. lab we Q as or univariable signed to and the two and universal AMR result UTI AMR a ongoing future well we a the univariable progressing discussions commercial or of first LRP on of added
a months several across currently numbers that annually commercial review. we believe and We indicates new customer expect universal with value option. And There With are revenue contracts potential seven Us figure in final believe weeks accounts are to growth Acuitas a the dollar product these significant this we combined increase and for ahead. in
final clinical FDA. forward subsequent trial regulatory submission are and universal UTI for our We UTI to data the looking to and a readout
of business, Our and our lab us and with generation signed and opened lower signing goals our We in processing was partnerships clinical our to X.X conversations on term sequencing for diagnostics revenue collaborate and which agreements. in NGS services a sequencing with expanding the of and include potential collaboration contracts samples million. to organizations as are new globally is here $X newly be XXXX the now anticipated for pharma NGS expect currently XXXX, the multiple well revenue UTI for up ramp collaborations accounts contracts longer trial, leading in and and for services services somewhere products Maryland, of than around of as next from range with Rockville, ongoing hundreds collaborations us
While expected, a have still XXXX. pipeline opportunities of revenue lower significant this in growth than is strong we expected with
the from Also, Our will collaboration, versus new XXXX. reflect proceeds income early in recognition recognized will soon expect we begin which in statement XXXX. fine qX to buyer the revenue into and the be collaboration from
In minimum August you. NASDAQ regain a requests price bid XXX compliance rule. with for x day NASDAQ X to nest branded For extension Listing options requirement. Under
the back not to XX than Oliver. one Oliver one. that are not XX about. stockholders but at to a meeting the to modules. and rule, I'll the November the a call less have of price XXXX, upon minimum which stock and end to ratio compliance authorize confident we achievements We than implement will There now discuss five regain until to with on company's split be To upcoming XXXX. proposal vote to February reverse a to of more bid a turn special board With
